

# ForPatients

*by Roche*

Idiopathic Pulmonary Fibrosis (IPF)

## A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

**Trial Status**  
Completed

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT02648048 2015-003481-81  
GB29764

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02648048 2015-003481-81 GB29764**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 40 Years & <= 80 Years

**Healthy Volunteers**  
No

---